Literature DB >> 2006137

Comparative modeling of mammalian aspartate transcarbamylase.

J L Scully1, D R Evans.   

Abstract

Mammalian aspartate transcarbamylase (ATCase) is part of a 243 kDa multidomain polypeptide, called CAD, that catalyzes the first three steps in de novo pyrimidine biosynthesis. The structural organization of the mammalian enzyme is very different from E. coli ATCase, a dodecameric, monofunctional molecule comprised of six copies of separate catalytic and regulatory chains. Nevertheless, sequence similarities and other properties suggested that the mammalian ATCase domain and the E. coli ATCase catalytic chain have the same tertiary fold. A model of mammalian ATCase was built using the X-ray coordinates of the E. coli catalytic chain as a tertiary template. Five small insertions and deletions could be readily accommodated in the model structure. Following energy minimization the RMS difference in the alpha carbon positions of the mammalian and bacterial proteins was 0.93 A. A comparison of the hydrophobic energies, surface accessibility index, and the distribution of hydrophilic and hydrophobic residues of the CAD ATCase structure with correctly and incorrectly folded proteins and with several X-ray structures supported the validity of the model. The mammalian ATCase domain associates to form a compact globular trimer, a prerequisite for catalysis since the active site is comprised of residues from adjacent subunits. Interactions between the clearly defined aspartate and carbamyl phosphate subdomains of the monomer were largely preserved while there was appreciable remodeling of the trimeric interfaces. Several clusters of basic residues are located on the upper surface of the domain which account in part for the elevated isoelectric point (pI = 9.4) and may represent contact regions with other more acidic domains within the chimeric polypeptide. A long interdomain linker connects the monomer at its upper surface to the remainder of the polypeptide. The configuration of active site residues is virtually identical in the mammalian and bacterial enzymes. While the CAD ATCase domain can undergo the local conformational changes that accompany catalysis in the E. coli enzyme, the high activity, closed conformation is probably more stable in the mammalian enzyme.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2006137     DOI: 10.1002/prot.340090305

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  7 in total

1.  Design, synthesis, and bioactivity of novel inhibitors of E. coli aspartate transcarbamoylase.

Authors:  Joby Eldo; Sabrina Heng; Evan R Kantrowitz
Journal:  Bioorg Med Chem Lett       Date:  2006-12-21       Impact factor: 2.823

2.  Expression, purification, crystallization and preliminary X-ray diffraction analysis of the aspartate transcarbamoylase domain of human CAD.

Authors:  Alba Ruiz-Ramos; Nada Lallous; Araceli Grande-García; Santiago Ramón-Maiques
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2013-11-29

3.  Substitutions in the aspartate transcarbamoylase domain of hamster CAD disrupt oligomeric structure.

Authors:  Y Qiu; J N Davidson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

4.  Subunit structure of a class A aspartate transcarbamoylase from Pseudomonas fluorescens.

Authors:  S T Bergh; D R Evans
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

5.  HomologyPlot: searching for homology to a family of proteins using a database of unique conserved patterns.

Authors:  J M Parker; R S Hodges
Journal:  J Comput Aided Mol Des       Date:  1994-04       Impact factor: 3.686

6.  Molecular structure of Bacillus subtilis aspartate transcarbamoylase at 3.0 A resolution.

Authors:  R C Stevens; K M Reinisch; W N Lipscomb
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

7.  Dynamics of the cellular metabolome during human cytomegalovirus infection.

Authors:  Joshua Munger; Sunil U Bajad; Hilary A Coller; Thomas Shenk; Joshua D Rabinowitz
Journal:  PLoS Pathog       Date:  2006-12       Impact factor: 6.823

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.